Durata skin infection meds gets thumbs up from FDA


The US Food and Drug Administration has approved a new drug to treat acute bacterial skin and skin structure infections made by Durata Therapeutics Inc. Approval of the drug, Dalvance, follows a positive recommendation by the FDA’s advisory committee, which also gave a favorable review to a rival product from Cubist Pharmaceuticals Inc. The FDA is set to rule on the Cubist drug shortly.

Read the source article at medcitynews.com

About the Author

Leave a Reply